



Client Reference: 1991-30-0020CP3C3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re: The Application of RAYCHAUDHURI et al.

Group Art Unit: 1653

Application No.: 10/743,398

Examiner: Unassigned

Filed: December 23, 2003

Confirmation No.: 7187

For: INDUCTION OF CYTOTOXIC T-LYMPHOCYTE RESPONSES

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Copies of references that were cited by the applicant or examiner during the prosecution of related prior applications, including U.S. Patent Nos. 5,585,103 issued December 17, 1996; 6,270,769 issued August 7, 2001; 5,709,860 issued January 20, 1998; 5,695,770 issued December 9, 1997; 6,197,311 issued March 6, 2001; and U.S. Application No. 09/740,003, filed on December 20, 2000, are not included. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed before the mailing date of the first official action on the merits in the present application. No certification or fee is required.


Respectfully submitted,

Thomas A. Cawley, Jr., Ph.D.
Registration Number 40,944

Date: May 21, 2004

PILLSBURY WINTHROP LLP
Telephone: (703) 905-2000
Facsimile: (703) 905-2500
P.O. Box 10500
McLean, VA 22102

TAC/CR:ntb



Atty.
Dkt. No.

M#

Client Ref.

037003-0307430

1991-30-0020CP3C3

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant: RAYCHAUDHURI et al.

Appln. No.: 10/743,398

Filing Date: December 23, 2003

Date: May 21, 2004

Page 1 of 3

Examiner: Unassigned

Group Art Unit:
1653

U.S. PATENT DOCUMENTS

Examiner's Initials		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date if appropriate
*	AR	3,083,142	03/1963	Howell			
*	BR	3,790,665	02/1974	Glass			
*	CR	3,919,411	11/1975	Glass			
*	DR	4,053,585	05/1976	Allison			
*	ER	4,117,113	11/1977	Allison			
*	FR	4,770,874	09/1988	Allison			
*	GR	4,772,466	09/1988	Allison			
*	HR	4,778,784	10/1988	Dreesman			
	IR	4,877,611	10/1989	Cantrell			
*	JR	4,963,354	06/1990	Shepard			
	KR	5,114,708	05/1992	Hunter			
	LR	5,234,683	08/1993	Hunter			
*	MR	5,585,103	12/1996	Raychaudhuri			
*	NR	5,695,770	12/1997	Raychaudhuri			
*	OR	5,709,860	01/1998	Raychaudhuri			
*	PR	6,270,769	08/2001	Raychaudhuri			

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclose	No
*	QR	0135376	03/1995	EP					
*	RR	0171496A2	2/1986	EP					
*	SR	0382271	08/1990	EP					
*	TR	0399843	11/1990	EP					
*	UR	0498767A2	8/1992	EP					
*	VR	0451216 B1	10/1991	EP					
*	WR	0460674A2	12/1991	EP					
*	XR	0682040 A1	11/1995	EP					
*	YR	WO 88/02634	4/1988	PCT					
*	ZR	WO 90/14837	12/1990	PCT					
*	AAR	WO 92/06113	Apr 1992	PCT	Van Wijnendale et al.	X		X	
*	BBR	WO 92/11291	Jul 1992	PCT	Van Wijnendale et al.	X		X	
*	CCR	WO 92/16231	Oct 1992	PCT	Francotte et al.	X		X	
*	DDR	WO 99/13912 A	03/1999	PCT	Braslawsky				
*	EER	GB 9105992.3	Mar 1991	GB	SmithKline	X		X	

* References were cited and/or submitted during prosecution of U.S. Patent Nos.: 5,585,103 issued December 17, 1996; 6,270,769 issued August 7, 2001; 5,709,860 issued January 20, 1998; 5,695,770 issued December 9, 1997; 6,197,311 issued March 6, 2001; and U.S. Application No. 09/740,003, filed on December 20, 2000.

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)			
*	FFR	Acres RB, et al., "Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumors bearing the MUC1 antigen," <i>J Immunother</i> , 1993, 14: 136-43.	
*	GGR	Allison AC, et al., "An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity," <i>J Immunol Methods</i> , 1986, 95:157-68.	
*	HHR	Allison AC, et al., "Vaccines: recent trends and progress," <i>Immunol Today</i> , 1990, 11: 427-9.	
*	IIR	Allison et al., <i>Vaccines 87</i> , Cold Spring harbor Laboratory (1987).	
*	JJR	Allison et al., <i>Immunopharmacology of Infectious Diseases: Vaccine Adjuvants and modulators of Non-Specific Resistance</i> , pp. 191-201, 1987.	
*	KKR	Allison, <i>Immunopotential</i> , Elsevier, Excerpta Medica, North-Holland, pp. 73-99, 1973.	
*	LLR	Allison, 1988, <i>Technological Advances in Vaccine Development</i> , pp. 401-409.	
*	MMR	Allison, "Non-Specific" Factors Influencing Host Resistance, pp. 247-258 (Karger, Basel 1973).	
*	NNR	Alwan WH, et al., "CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells," <i>Clin Exp Immunol</i> , 1992, 88: 527-36.	
*	OOR	Asherson GL, et al., "Production of delayed hypersensitivity by antigen associated with peritoneal exudate cells and the effect of pretreatment with Freund's complete adjuvant," <i>Immunology</i> , 1972, 22: 465-73.	
*	PPR	Berman LD, et al., "Effects of Freund's adjuvant on adenovirus oncogenesis and antibody production in hamsters," <i>Int J Cancer</i> , 1967, 2: 539-43.	
*	QQR	Brugh M, et al., "Comparison of inactivated Newcastle disease viral vaccines containing different emulsion adjuvants," <i>Am J Vet Res</i> , 1983, 44: 72-5.	
*	RRR	Byars NE, et al., "Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity," <i>Vaccine</i> , 1987, 5: 223-8.	
*	SSR	Byars NE, et al., "Enhancement of antibody responses to influenza B virus haemagglutinin by use of a new adjuvant formulation," <i>Vaccine</i> , 1990, 8: 49-56.	
*	TTR	Campbell MJ, et al., "Idiotypic vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits," <i>J Immunol</i> , 1987, 139: 2825-33.	
*	UUR	Campbell MJ, et al., "Idiotypic vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity," <i>J Immunol</i> , 1990, 145: 1029-36.	
*	VVR	Chemical and Physical Properties Emulsifiers, <i>Uniqema</i> , Paper FF/E/03-01/AMERI/14/500.	
*	WWR	Eppstein et al., <i>Advanced Drug Deliver Reviews</i> , 4:233-253, 1990.	
*	XXR	Ghossein RA, et al., 1995, "Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications," <i>J Clin Oncol.</i> , 13(5):1195.	
*	YYR	Goldstein et al., Chapter 4, <i>mAbs To Human Lymphocyte Surface Antigens</i> , p. 71.	
*	ZZR	Harada, M. et al., 1994, "Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2," <i>Cancer Immunol Immunother.</i> , 38:332-338.	
*	AAAR	Horiguchi Y, et al., 2002, "Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes," <i>Clin Cancer Res</i> , 8(12):3885-3892.	
*	BBBR	Hunter R, et al., "Mechanisms of action of nonionic block copolymer adjuvants," <i>Aids Research and Human Retroviruses</i> , 1994, 10(2):595-8.	
*	CCCR	Hunter R, et al., "The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile-lipophile balance," <i>J Immunol.</i> , 1981, 127:1244-50.	
*	DDDR	Hunter RL, et al., "The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers," <i>J Immunol</i> , 1984, 133: 3167-75.	
*	EEER	Hunter R, et al., "Adjuvant activity of non-ionic block copolymers. IV. Effect of molecular weight and formulation on titre and isotype of antibody," <i>Vaccine</i> , 1991, 9:250-6.	
*	FFFR	Ioannides C.G. and Whiteside T.L., 1993, "Short Analytical Review: T Cell Recognition of Human Tumors: Implications for Molecular Immunotherapy of Cancer," <i>Clinical Immunology and Immunopathology</i> , 66(2):91-106.	
*	GGGR	Israeli RS, et al., 1993, "Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen," <i>Cancer Res</i> , 53(2):227-230.	
*	HHHR	Kahn M, et al., "CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen," <i>J Immunol.</i> , 1991, 146:3235-41.	
*	IIIR	Kenney JS, et al., "Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies," <i>J Immunol Methods</i> , 1989, 121: 157-66.	
*	JJJR	Khusmith S, et al., "Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein," <i>Science</i> , 1991, 252: 715-8.	
*	KKKR	Kimura J, et al., "Studies on the adjuvant effect of water-in-oil-in-water (w/o/w) emulsion of sesame oil. 1. Enhanced and persistent antibody formation by antigen incorporated into the water-in-oil-i-water emulsion," <i>Jpn J Exp Med</i> , 1978, 48:149-54.	
*	LLLR	Kolata, New York Times.	

*	MMMR	Korstvedt, H. et al., 1984, <i>Drug Cosmet Ind</i> , 135, 36-37.
*	NNNR	Kwak LW, et al., "Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotype immunoglobulin," <i>Blood</i> , 1990, 76: 2411-7.
*	OOOR	Kwak et al., "Idiotype vaccination for patients with B-cell lymphoma," <i>Idiotype Networks in Bio and Med.</i> , 1990 Elsevier Sci. Pub. B.V., 163-171.
*	PPPR	Lee et al., Surfactant Effect on the Stability and Electroheological Properties of Polyaniline Particle Suspension, <i>Jour. Of Colloid & Interface Science</i> , 206, 424-438 (1998), CS985661.
*	QQQR	Letvin et al., <i>Vaccines 87</i> , Cold Spring harbor Laboratory (1987).
*	RRRR	Lidgate, D.M., et al., 1989, <i>Biopharm</i> , 2:28-32.
*	SSSR	Maa et al., "Performance of Sonication and Microfluidization for Liquid-Kiquid Emulsification," <i>Phar. Dev & Tech.</i> , 4(2), 233-240 (1999).
*	TTTR	Mackewicz CE, et al., "CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual," <i>J Clin Invest</i> , 1991, 87: 1462-6.
*	UUUR	McLaughlin, JP, et al., 1996, "Improved Immunotherapy of a Recombinant Carcinoembryonic Antigen Vaccinia Vaccine When Given in Combination with Interleukin-2," <i>Cancer Research</i> , 56:2361-2367.
*	VVVR	Mitchell MS, et al., "Active-specific immunotherapy for melanoma," <i>J Clin Oncol</i> , 1990, 8: 856-69.
*	WWWR	Morein et al., <i>Immunological Adjuvants and Vaccines</i> , Plenum Press, Published in cooperation with NATO Science Affairs Division, pp. 153-161.
*	XXXR	Morgan AJ, et al., "Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use," <i>J Med Virol</i> , 1989, 29: 74-8.
*	YYR	Murphey-Corb M, et al., "A formalin-inactivated whole SIV vaccine confers protection in macaques," <i>Science</i> , 1989, 246: 1293-7.
*	ZZZR	Nicholas JA, et al., "Cytotoxic T cell activity against the 22-kDa protein of human respiratory syncytial virus (RSV) is associated with a significant reduction in pulmonary RSV replication," <i>Virology</i> , 1991, 182: 664-72.
*	AAAAR	Peace DJ, et al., "Induction of T cells specific for the mutated segment of oncogenic P21ras protein by immunization in vivo with the oncogenic protein," <i>J Immunother</i> , 1993, 14: 110-4.
*	BBBBR	Phillips NC, et al., "Clinical evaluation of liposomal tumor antigen vaccines in patients with stage-III melanoma," <i>Cancer Detect Prev</i> , 1990, 14: 491-6.
*	CCCCR	Rennie, <i>Scientific American</i> , Jul. 1991, p. 24.
*	DDDDR	Rickman LS, et al., "Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine," <i>Lancet</i> , 1991, 337: 998-1001.
*	EEEEER	Sanchez-Pescador L, et al., "The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine," <i>J Immunol</i> , 1988, 141: 1720-7.
*	FFFFR	Sanda MG, et al., "Molecular characterization of defective antigen processing in human prostate cancer," <i>J Natl Cancer Inst</i> , 1995, 87: 280-5.
*	GGGGR	Shen L, et al., "Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes," <i>Science</i> , 1991, 252: 440-3.
*	HHHHR	Staerz UD, et al., "Cytotoxic T lymphocytes against a soluble protein," <i>Nature</i> , 1987, 329: 449-51.
*	IIIR	Stover CK, et al., "New use of BCG for recombinant vaccines," <i>Nature</i> , 1991, 351: 456-60.
*	JJJJR	Takahashi H, et al., "An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes," <i>Proc Natl Acad Sci U S A</i> , 1988, 85: 3105-9.
*	KKKKR	Takahashi H, et al., "Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs," <i>Nature</i> , 1990, 344: 873-5.
*	LLLLR	Takayama K, et al., "Adjuvant activity of non-ionic block copolymers. V. Modulation of antibody isotype by polysaccharides, lipid A and precursors," <i>Vaccine</i> , 1991, 9: 257-65.
*	MMMMR	Tsang, D.Y., et al., 1995, "Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From patients Immunized with Recombinant Vaccinia-CEA Vaccine," <i>J of the Nat'l Cancer Inst.</i> , 87(13):982.
*	NNNNR	WALKER et al., "Priming of Cytotoxic T Lymphocyte Responses with Recombinant HIV Envelope Proteins in Murine and Primate Models," <i>Humheme Colloque Des Cent Gardes</i> , 1993, 321-325.
*	OOOOR	Wraith DC, et al., "Induction of influenza A virus cross-reactive cytotoxic T cells by a nucleoprotein/ haemagglutinin preparation," <i>J Gen Virol</i> , 1985, 66 (Pt 6): 1327-31.
*	PPPPR	Xue, BH, et al., 1997, "Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen," <i>Prostate</i> , 30(2):73-78.
*	QQQQR	Yin et al., 1993, <i>Leukemia</i> 7 Suppl 2 527-30.

Examiner

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.